{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T13:45:03Z","timestamp":1770471903649,"version":"3.49.0"},"reference-count":30,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,7,7]],"date-time":"2008-07-07T00:00:00Z","timestamp":1215388800000},"content-version":"vor","delay-in-days":2728,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2001,1,17]]},"abstract":"<jats:p>Highly selective inhibitors of cyclooxygenase\u20102, such as rofecoxib, are hypothesized to have an improved gastrointestinal tolerability and safety profile compared with non\u2010selective NSAIDs, which inhibit cyclooxygenase\u20101 and cyclooxygenase\u20102 non\u2010selectively. This paper reviews data from randomized, double\u2010blind, placebo\u2010controlled studies which investigated the effects of rofecoxib and NSAIDs on the human gastrointestinal tract.<\/jats:p><jats:p>In healthy subjects, rofecoxib 25\u2003mg and 50\u2003mg daily had no effect on gastric mucosal prostaglandin synthesis, whilst naproxen 1000\u2003mg daily caused a 70% reduction. Therapeutic doses of rofecoxib 25\u2003mg and 50\u2003mg daily did not increase intestinal permeability or faecal blood loss in healthy subjects, whereas increases in both measures were seen with indometacin 150\u2003mg or ibuprofen 2400\u2003mg. A supra\u2010therapeutic dose of rofecoxib (250\u2003mg) given daily for 7\u2003days did not induce an increase in gastroduodenal erosions in healthy subjects, whilst increased numbers of erosions were found in subjects given ibuprofen 2400\u2003mg or aspirin 2600\u2003mg.<\/jats:p><jats:p>The endoscopic findings in healthy subjects were confirmed in two 6\u2010month clinical studies involving 1516 patients with osteoarthritis; the incidences of ulcers following rofecoxib 25\u2003mg or 50\u2003mg daily were similar to placebo and less than ibuprofen 2400\u2003mg. The advantage of rofecoxib over NSAIDs in these studies appears to translate into clinically relevant benefits; an analysis of 5435 patients with osteoarthritis found a significantly lower incidence of gastrointestinal perforations, ulcers and bleeds in patients taking rofecoxib compared with patients taking NSAIDs.<\/jats:p><jats:p>Overall, the findings from these studies suggest that, as a result of cyclooxygenase\u20101 sparing, rofecoxib is significantly less gastrotoxic than non\u2010selective NSAIDs, and may not differ from placebo.<\/jats:p>","DOI":"10.1046\/j.1365-2036.2001.00894.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:43:00Z","timestamp":1047354180000},"page":"1-9","source":"Crossref","is-referenced-by-count":33,"title":["The gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase\u20102, in humans"],"prefix":"10.1111","volume":"15","author":[{"given":"C. J.","family":"Hawkey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. E.","family":"Harper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. J.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. R.","family":"Lines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,7,7]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(89)80061-7"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199906173402407"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00072-2"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-114-4-257"},{"key":"e_1_2_7_6_2","doi-asserted-by":"crossref","unstructured":"VaneJR&BotttingRM.Overview\u2014mechanisms of action of anti\u2010inflammatory drugs. In: Vane J Botting J Botting R eds. Improved Non\u2010Steroidal Anti\u2010Inflammatory Drugs: COX\u20102 Enzyme Inhibitors. Boston: Kluwer Academic Publishers 1996: 1\u201327.","DOI":"10.1007\/978-94-010-9029-2_1"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.13.7563"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(98)12154-2"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0960-894x(99)00288-7"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.12.1781"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70113-X"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0029-7844(99)00360-9"},{"key":"e_1_2_7_14_2","unstructured":"Merck & Co. Inc.Vioxx (Rofecoxib Tablets and Oral Suspension). Phyicians Desk Reference. Montvale NJ: Medical Economics Company 2000: 1912\u20135."},{"key":"e_1_2_7_15_2","first-page":"551","article-title":"Rofecoxib [Vioxx, MK\u20100966; 4\u2010(4\u2032\u2010methylsulfonylphenyl)\u20103\u2010phenyl\u20102\u2010(5H)\u2010furanone]: a potent and orally active cyclooxygenase\u20102 inhibitor. Pharmacological and biochemical profiles","volume":"290","author":"Chan C","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_16_2","first-page":"1907","article-title":"In vivo effects of rofecoxib, a new cyclooxygenase (COX)\u20102 inhibitor, on gastric mucosal prostaglandin (PG) and serum thromboxane B2 (TXB2) synthesis in healthy humans","volume":"91","author":"Cryer B","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_7_17_2","first-page":"A25","article-title":"Evidence that the COX\u20102 specific inhibitor rofecoxib at 50\u2003mg spares gastric mucosal prostaglandin synthesis in humans","volume":"45","author":"Wright N","year":"1999","journal-title":"Gut"},{"key":"e_1_2_7_18_2","first-page":"118","article-title":"Demonstration of specific COX\u20102 inhibition by MK\u2010966 (VIOXX) in humans with supratherapeutic doses","volume":"27","author":"Depre E","year":"1998","journal-title":"Rheum Eur"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.3109\/03009748709096722"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.47.4.527"},{"key":"e_1_2_7_21_2","first-page":"36","article-title":"Gastrointestinal microbleeding: comparisons between benoxaprofen and other nonsteroidal antiinflammatory agents","volume":"7","author":"Ridolfo AS","year":"1980","journal-title":"J Rheumatol"},{"key":"e_1_2_7_22_2","unstructured":"HuntR BowenB&MortensenE et\u2003al.Fecal blood loss after specific inhibition of cyclooxygenase\u20102: treatment with rofecoxib compared with ibuprofen and placebo.Am J Med2000; in press."},{"key":"e_1_2_7_23_2","first-page":"338","article-title":"An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa","volume":"14","author":"Lanza F","year":"1987","journal-title":"J Rheumatol"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00529.x"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70334-3"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D"},{"key":"e_1_2_7_27_2","first-page":"133","article-title":"Effect of rofecoxib on endoscopic ulcers in osteoarthritis patients: analysis of potential risk factors","volume":"59","author":"Hawkey C","year":"2000","journal-title":"Ann Rheumatic Diseases"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701672"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v112.pm9024292"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.20.1929"},{"key":"e_1_2_7_31_2","first-page":"S403","article-title":"Treatment with rofecoxib required less gastrointestinal (GI) co\u2010medication and fewer GI procedures than non\u2010specific cyclooxygenase inhibitors (NSAIDs)","volume":"42","author":"Watson DJ","year":"1999","journal-title":"Arthritis Rheum"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.00894.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.00894.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2001.00894.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T22:47:42Z","timestamp":1697496462000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2001.00894.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1,17]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1,17]]}},"alternative-id":["10.1046\/j.1365-2036.2001.00894.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2001.00894.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1,17]]}}}